DDIS-20. IMIPRIDONE STRUCTURE ACTIVITY RELATIONSHIP UNCOVERS ONC206 AS THE NEXT BITOPIC DRD2 ANTAGONIST FOR ONCOLOGY WITH DIFFERENTIATED RECEPTOR PHARMACOLOGY

ONC201 is the first bitopic antagonist of dopamine receptor D2 (DRD2) in oncology clinical trials, which have shown that the small molecule is well tolerated and induces durable tumor regressions in H3 K27M-mutant glioma patients. ONC201 possesses a unique tri-heterocyclic core structure that prompt...

Full description

Saved in:
Bibliographic Details
Published in:Neuro Oncol
Main Authors: Prabhu, Varun, Cuoco, Caroline, Jung, Jinkyu, Rahman Kawakibi, Abed, Willette, Blair, Day, Marilyn, Anantharaman, Lakshmi, Charter, Neil, Rucker, Joseph, Doranz, Benjamin, Oster, Wolfgang, Stogniew, Martin, Gilbert, Mark, Benjamin Free, R, Sibley, David, Allen, Joshua
Format: Artigo
Language:Inglês
Published: Oxford University Press 2019
Subjects:
Drug Discovery
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC6846870/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz175.271
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items